辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFE 辉瑞

盘后交易 04-26 19:03:28 EDT

25.40

+0.14

+0.55%

盘后25.44

+0.04+0.16%

19:01 EDT

最高25.54	最低25.20	成交量4,651万
今开25.33	昨收25.26	日振幅1.35%
总市值1,438亿	流通市值1,436亿	总股本56.63亿
成交额11.82亿	换手率0.82%	流通股本56.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":25.4,"timestamp":1714161600000,"preClose":25.26,"halted":0,"volume":46511213,"hourTrading":{"tag":"盘后","latestPrice":25.4399,"preClose":25.4,"latestTime":"19:01 EDT","volume":4060986,"amount":103150546.96482,"timestamp":1714172507281},"delay":0,"floatShares":5653840796,"shares":5662541291,"eps":0.367372,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.14,"latestTime":"04-26 19:03:28 EDT","open":25.33,"high":25.54,"low":25.2,"amount":1181910340.3956869,"amplitude":0.01346,"askPrice":25.46,"askSize":271,"bidPrice":25.42,"bidSize":234,"shortable":3,"etf":0,"ttmEps":0.367372,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1714176000000},"adr":0,"listingDate":-819144000000,"adjPreClose":25.26,"adrRate":0,"dividendRate":0.064567,"preHourTrading":{"tag":"盘前","latestPrice":25.32,"preClose":25.26,"latestTime":"09:29 EDT","volume":323654,"amount":8238095.3709080005,"timestamp":1714138199057},"postHourTrading":{"tag":"盘后","latestPrice":25.4399,"preClose":25.4,"latestTime":"19:01 EDT","volume":4060986,"amount":103150546.96482,"timestamp":1714172507281},"volumeRatio":1.363498,"optionData":{"bulkOrders":[{"symbol":"PFE","call":false,"expireDate":1781755200000,"strike":"32.0","timestamp":1714154567608,"price":8,"volume":1100,"amount":880000,"type":"-"}]}},"requestUrl":"/m/hq/s/PFE?invite=033TIGER","defaultTab":"news","newsList":[{"id":"2430738412","title":"辉瑞在美国获批的首个基因疗法！治疗B型血友病","url":"https://stock-news.laohu8.com/highlight/detail?id=2430738412","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2430738412?lang=zh_cn&edition=full","pubTime":"2024-04-27 03:24","pubTimestamp":1714159444,"startTime":"0","endTime":"0","summary":"辉瑞公司开发的基因疗法Beqvez已获得美国食品和药物管理局（FDA）的正式批准，用于治疗中度至重度的B型血友病成年患者。有分析指出，这一批准标志着辉瑞公司在新冠疫情期间业务急剧下滑后，力图重振旗鼓的重要一步。","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/6736cb3e-fd7f-4186-b23e-a5fe060794e4.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/6736cb3e-fd7f-4186-b23e-a5fe060794e4.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3713760","is_publish_highlight":false,"gpt_icon":0},{"id":"2430470224","title":"美国食品和药物管理局批准辉瑞基因疗法治疗罕见出血性疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2430470224","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430470224?lang=zh_cn&edition=full","pubTime":"2024-04-26 18:46","pubTimestamp":1714128415,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月26日 - 美国食品和药物管理局周五批准了辉瑞公司  治疗B型血友病的基因疗法，这是针对这种通常需要定期输注凝血蛋白的罕见出血性疾病的第二种此类疗法。血友病患者体内有一种调节凝血因子蛋白质生成的基因发生了缺陷，这种缺陷可能导致自发性出血以及受伤或手术后的严重出血。这种疾病主要影响男性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430133522","title":"成都先导与辉瑞合作开发出适用于DEL的异喹诺酮骨架合成方法","url":"https://stock-news.laohu8.com/highlight/detail?id=2430133522","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2430133522?lang=zh_cn&edition=full","pubTime":"2024-04-26 12:27","pubTimestamp":1714105620,"startTime":"0","endTime":"0","summary":"证券时报e公司讯，据成都先导消息，近日，成都先导与辉瑞公司在适用于DNA编码化合物库(DNA-Encodedlibrary，DEL)的异喹诺酮骨架合成方法探索上取得重要突破——通过三价铑催化的碳氢活化反应成功实现了DNA上异喹诺酮骨架的关环。进一步实验证明该方法能够用于DEL的合成。该方法条件温和，底物适用性广，提供了更多的分子多样性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261228178b558518&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261228178b558518&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430323586","title":"BUZZ-辉瑞、BioNTech 因葛兰素史克起诉 COVID-19 疫苗技术而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2430323586","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430323586?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:50","pubTimestamp":1714060208,"startTime":"0","endTime":"0","summary":"    4月25日 - ** 疫苗生产商辉瑞  和BioNTech  的股价下跌2%至3%。** 制药商葛兰素史克  起诉  BNTX和PFE，指控它们侵犯了其与信使核糖核酸 技术有关的专利，该技术应用于这两家公司的大片COVID-19疫苗中。** 葛兰素史克称，PFE 和 BNTX 的 Comirnaty 疫苗侵犯了其在 mRNA 疫苗创新方面的专利权，这些创新是在 COVID-19 大流行爆发 \"十多年前 \"开发的。** 葛兰素史克还要求特拉华州联邦法院向这两家公司支付数额不详的赔偿金，其中包括持续的专利许可费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430355922","title":"辉瑞下跌3.06%，报25.47美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430355922","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430355922?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:46","pubTimestamp":1714059962,"startTime":"0","endTime":"0","summary":"4月25日，辉瑞(PFE)盘中下跌3.06%，截至23:46，报25.47美元/股，成交4.3亿美元。财务数据显示，截至2023年12月31日，辉瑞收入总额584.96亿美元，同比减少41.7%；归母净利润21.19亿美元，同比减少93.25%。大事提醒：5月1日，辉瑞将于(美东)盘前披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/25234640416047.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430428593","title":"葛兰素史克就 Covid-19 疫苗技术起诉辉瑞和 BioNTech","url":"https://stock-news.laohu8.com/highlight/detail?id=2430428593","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430428593?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:35","pubTimestamp":1714052123,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) Blake Brittain    路透社4月25日 - 葛兰素史克公司  周四在特拉华州联邦法院起诉辉瑞  和BioNTech  ，指控它们侵犯了葛兰素史克公司与信使RNA(mRNA) 技术有关的专利权，这些技术应用于这两家公司的大片COVID-19疫苗中。葛兰素史克在诉讼中说，辉瑞和 BioNTech 的 Comirnaty 疫苗侵犯了该公司在 mRNA 疫苗创新方面的专利权，而这些创新是在 COVID-19 大流行爆发 \"十多年前 \"开发的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429139311","title":"一药治三病！辉瑞(PFE.US)&艾伯维(ABBV.US)小分子疗法获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2429139311","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429139311?lang=zh_cn&edition=full","pubTime":"2024-04-23 11:25","pubTimestamp":1713842723,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，辉瑞宣布，欧盟委员会批准其与艾伯维联合开发的Emblaveo上市，用于治疗成人复杂性腹腔内感染、医院获得性肺炎，以及复杂性尿路感染。根据新闻稿，Emblaveo是首个在欧盟获批使用的β-内酰胺/β-内酰胺酶抑制剂组合，用于治疗由多重耐药革兰氏阴性菌引起的严重细菌感染成人患者。Emblaveo是aztreonam和avibactam这两种抗生素的组合。辉瑞拥有在美国和加拿大以外地区商业化该疗法的全球权利，而艾伯维则拥有Emblaveo在美国和加拿大的权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107359.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429930940","title":"年销6亿元的进口药倒在了 “红线价”上，辉瑞阿奇霉素干混悬剂面临撤网，原研药撤退潮来袭","url":"https://stock-news.laohu8.com/highlight/detail?id=2429930940","media":"华夏时报","top":-1,"share":"https://www.laohu8.com/m/news/2429930940?lang=zh_cn&edition=full","pubTime":"2024-04-20 17:03","pubTimestamp":1713603790,"startTime":"0","endTime":"0","summary":"本报（chinatimes.net.cn）记者于娜 北京报道原研药在国内市场上开始的“撤退潮“有些措不及防。去年秋季开始的那一波支原体感染潮中，备受家长追捧的“进口药”辉瑞的阿奇霉素干混悬剂或将在河北省所有的公立医院中消失。近日，河北省医用药品器械集中采购中心发布《关于公布第九批国家带量采购同通用名未中选药品的通知》...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OsRNJOchSDaxyRWSifJWvU4WC_swMqLT4b1sa2s3gWTYAAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OsRNJOchSDaxyRWSifJWvU4WC_swMqLT4b1sa2s3gWTYAAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240420A05L2S00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240420A05L2S00","is_publish_highlight":false,"gpt_icon":0},{"id":"2428159088","title":"坎托菲茨杰拉德公司：重申Pfizer(PFE.US)评级，由增持调整至增持评级, 目标价45.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428159088","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428159088?lang=zh_cn&edition=full","pubTime":"2024-04-18 22:15","pubTimestamp":1713449711,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Pfizer(PFE.US)评级，由增持调整至增持评级, 目标价45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404182215158790b8eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404182215158790b8eb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428790561","title":"减肥药开发商 Metsera 获得 2.9 亿美元融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2428790561","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428790561?lang=zh_cn&edition=full","pubTime":"2024-04-18 19:09","pubTimestamp":1713438543,"startTime":"0","endTime":"0","summary":"Metsera公司由风险投资公司ARCH Venture和投资公司Population Health Partners于2022年成立，目前正在开发基于GLP-1机制和其他生物靶点的治疗肥胖症的注射和口服药物。Meanwell 说，Metsera 的 2.9 亿美元融资是迄今为止从领先的医疗保健投资者银团筹集到的资金总额，包括种子轮和 A 轮融资。Meanwell 拒绝就融资的估值发表评论。Meanwell曾担任The Medicines Company首席执行官近20年，该公司于2019年被瑞士制药商诺华  以97亿美元收购， 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428011268","title":"健康巡讲：RSV 感染会增加未接种疫苗成年人的心脏风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2428011268","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428011268?lang=zh_cn&edition=full","pubTime":"2024-04-17 03:05","pubTimestamp":1713294322,"startTime":"0","endTime":"0","summary":"未接种疫苗的成年人感染 RSV 会增加心脏风险一项新的研究显示，未接种疫苗的老年人因感染呼吸道合胞病毒 而住院治疗时，心脏事件很常见。研究人员周一在《美国医学会杂志》  上报告说，在因感染 RSV 而住院的 6,248 名 50 岁或以上未接种疫苗的美国成年人中，超过五分之一的人经历了急性心脏事件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427649730","title":"辉瑞下跌1.21%，报26.02美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427649730","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427649730?lang=zh_cn&edition=full","pubTime":"2024-04-13 00:40","pubTimestamp":1712940003,"startTime":"0","endTime":"0","summary":"4月13日，辉瑞(PFE)盘中下跌1.21%，截至00:40，报26.02美元/股，成交3.29亿美元。财务数据显示，截至2023年12月31日，辉瑞收入总额584.96亿美元，同比减少41.7%；归母净利润21.19亿美元，同比减少93.25%。大事提醒：5月1日，辉瑞将于(美东)盘前披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/13004040224308.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426785627","title":"BUZZ-摩根大通认为辉瑞公司的 COVID 治疗药物 Paxlovid 第一季度销售额有所增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2426785627","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426785627?lang=zh_cn&edition=full","pubTime":"2024-04-12 19:48","pubTimestamp":1712922482,"startTime":"0","endTime":"0","summary":"** 根据目前Paxlovid的发展趋势，券商认为PFE的全年预测有上调空间，但预计PFE不会上调预测。** 预计第一季度美国Paxlovid总销售额为10亿美元，而LSEG预计为11.2亿美元 ** 补充说，COVID 的上扬不足以在短期内推动股价，并称 PFE 需要在管线方面取得进一步进展，才能改变当前的股价走势。** 预计 PFE 的 COVID 疫苗 Comirnaty 大约 80-90% 的销售额将在今年下半年实现，因此券商认为第一季度的业绩没有什么额外的亮点，估计 Comirnaty 的销售额约为 5.5 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426783006","title":"BUZZ-Nurix Therapeutics 在增发 1.75 亿美元股票后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2426783006","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426783006?lang=zh_cn&edition=full","pubTime":"2024-04-12 19:37","pubTimestamp":1712921821,"startTime":"0","endTime":"0","summary":"    4月12日 - ** Nurix Therapeutics Inc 的    股价在隔夜后续定价后盘前下跌 5.3%，报 16.30 美元。** 生物制药公司周四晚些时候宣布，  ~1170万股，包括150万份预筹资认股权证，发行价为15美元，筹资总额为1.75亿美元。** Nurix本月早些时候宣布延长与吉利德科学公司  的合作。2023 年第四季度，该公司与辉瑞  达成新的合作。** Nurix 拥有约 4 920 万股已发行股票，市值约 8.46 亿美元** 截至本周四，公司股价已累计上涨 67** 摩根大通、Piper Sandler 和 Stifel 担任股票发行的账簿管理人","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426422642","title":"隔夜美股全复盘(4.11)| 三大股指集体收跌，美国CPI数据连续第三个月高于预期，股市承压于美国CPI数据后的降息预期收缩，英伟达逆势涨近2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426422642","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2426422642?lang=zh_cn&edition=full","pubTime":"2024-04-11 07:18","pubTimestamp":1712791107,"startTime":"0","endTime":"0","summary":"三大股指集体收跌，美国CPI数据连续第三个月高于预期，股市承压于美国CPI数据后的降息预期收缩，英伟达逆势涨近2%","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/717886","is_publish_highlight":false,"gpt_icon":1},{"id":"2426108847","title":"辉瑞(PFE.US)RSV疫苗用于18-59岁高危人群三期临床成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2426108847","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2426108847?lang=zh_cn&edition=full","pubTime":"2024-04-10 09:13","pubTimestamp":1712711625,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月9日，辉瑞宣布RSV疫苗Abrysvo用于18-59岁高危人群的三期临床获得积极数据，研究达到主要重点，免疫响应非劣效于60岁以上人群。辉瑞计划递交这一人群的上市申请。据了解，RSV高危人群是指特定慢性疾病的成年人。对于18-49岁成年人，9.5%的人群患有慢性疾病使得RSV感染风险提高，50-64岁这一比例则提高到24.3%。这些慢性疾病包括哮喘、糖尿病、COPD等。B组入组200例免疫不全18岁以上人群，其中一般为60岁以上人群。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100368.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426577116","title":"BUZZ-辉瑞公司在针对 60 岁以下高风险成人的研究中成功注射 RSV 疫苗，从而使其业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2426577116","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426577116?lang=zh_cn&edition=full","pubTime":"2024-04-09 22:59","pubTimestamp":1712674751,"startTime":"0","endTime":"0","summary":"** PFE表示，它计划提交研究结果，以寻求扩大该疫苗在18至59岁成年人中的批准范围。** 试验涉及 681 名 18 至 59 岁的成年人，他们患有哮喘、糖尿病和慢性阻塞性肺病等疾病，这些疾病会增加 RSV 的风险** RSV 通常会引起类似感冒的症状，是导致幼儿和老年人肺炎的主要原因。** PFE 去年推出了针对老年人和孕妇的 Abrysvo，以保护婴儿免受病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426133051","title":"辉瑞上涨3.14%，报27.42美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426133051","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426133051?lang=zh_cn&edition=full","pubTime":"2024-04-09 22:26","pubTimestamp":1712672805,"startTime":"0","endTime":"0","summary":"4月9日，辉瑞(PFE)盘中上涨3.14%，截至22:26，报27.42美元/股，成交3.12亿美元。财务数据显示，截至2023年12月31日，辉瑞收入总额584.96亿美元，同比减少41.7%；归母净利润21.19亿美元，同比减少93.25%。大事提醒：5月1日，辉瑞将于(美东)盘前披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/09222640170758.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425343189","title":"辉瑞研究表明P药并非“新冠神药”， 还有必要吃吗","url":"https://stock-news.laohu8.com/highlight/detail?id=2425343189","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2425343189?lang=zh_cn&edition=full","pubTime":"2024-04-08 14:31","pubTimestamp":1712557860,"startTime":"0","endTime":"0","summary":"上周末，一项由辉瑞抗病毒药物开发负责人领衔的研究结果显示，新冠期间被称为“新冠神药”的Paxlovid在缩短新冠持续症状时间方面并没有显著效果。其中，共有654名参与者服用Paxlovid，634名参与者服用安慰剂。缓解新冠症状持续时间为该临床试验的主要终点。P药组有5名参与者因新冠住院或死亡，安慰剂组有10名参与者因新冠住院或死亡。过去一年来，辉瑞股价累计跌幅超过35%。不过，新冠药物的研发仍在进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081432427a514b10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081432427a514b10&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424796018","title":"辉瑞下跌1.22%，报27.22美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424796018","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424796018?lang=zh_cn&edition=full","pubTime":"2024-04-04 03:20","pubTimestamp":1712172023,"startTime":"0","endTime":"0","summary":"4月4日，辉瑞(PFE)盘中下跌1.22%，截至03:20，报27.22美元/股，成交6.63亿美元。财务数据显示，截至2023年12月31日，辉瑞收入总额584.96亿美元，同比减少41.7%；归母净利润21.19亿美元，同比减少93.25%。大事提醒：4月1日，辉瑞获Cantor Fitzgerald重申评级Overweight，目标价上调至45美元。5月7日，辉瑞将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/04032040122430.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":-0.0051},{"period":"1month","weight":-0.0845},{"period":"3month","weight":-0.0805},{"period":"6month","weight":-0.1611},{"period":"1year","weight":-0.3461},{"period":"ytd","weight":-0.1226}],"compareEarnings":[{"period":"1week","weight":0.0079},{"period":"1month","weight":-0.0295},{"period":"3month","weight":0.033},{"period":"6month","weight":0.226},{"period":"1year","weight":0.2452},{"period":"ytd","weight":0.0593}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.00126},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.007167},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015985},{"month":4,"riseRate":0.6,"avgChangeRate":0.019186},{"month":5,"riseRate":0.5,"avgChangeRate":0.00626},{"month":6,"riseRate":0.5,"avgChangeRate":0.002739},{"month":7,"riseRate":0.477273,"avgChangeRate":0.010684},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.000087},{"month":9,"riseRate":0.454545,"avgChangeRate":0.004027},{"month":10,"riseRate":0.659091,"avgChangeRate":0.014878},{"month":11,"riseRate":0.704545,"avgChangeRate":0.030213},{"month":12,"riseRate":0.5,"avgChangeRate":0.0093}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}